Biotech Startups

Kamau Therapeutics develops targeted gene integration therapies to treat serious and life-threatening genetic diseases. The company is a clinical-stage biotech firm focused on next-generation gene correction.

4 investors

Kascaid develops immune-monitoring technology that samples interstitial fluid instead of blood to capture more stable, cell-free molecular signals of immune activity. Its diagnostic platform targets applications in drug development and patient care.

4 investors

Keriton offers a software platform for neonatal and pediatric hospital settings that supports safe infant feeding practices, milk management (donor human milk, formula, and parental human milk), and family engagement through features like secure photo sharing, e-journaling, and clinician messaging. It also provides reporting tools for clinical leaders to support operational decisions and quality improvement in NICU workflows.

4 investors

Keros is a clinical-stage biopharmaceutical company developing product candidates that modulate signaling of the transforming growth factor-beta (TGF-β) family of proteins to treat disorders affecting blood cells and tissues such as bone, muscle, adipose and heart. Its pipeline targets neuromuscular diseases and ineffective hematopoiesis in myelodysplastic syndromes and myelofibrosis.

4 investors

Kimialys provides antibody selection and kinetic characterization services using proprietary Surface Plasmon Resonance imaging (SPRi) technology and K-One surface chemistry for researchers and diagnostics developers. The platform enables rapid identification of optimal antibody candidates for diagnostic assays and therapeutic development across multiple assay formats.

4 investors

Kinish uses plant molecular farming on 20cm dwarf rice grown in plant factories to produce milk proteins, creating dairy alternatives such as ice cream and cheese without animal sources. The company develops plant-based food products aimed at matching the taste of conventional dairy for sustainability-focused consumers.

4 investors

KiraGen Bio develops cell-therapy approaches aimed at treating brain cancers, with a focus on therapies designed to remain functional under suppressive tumor conditions. Its work targets pediatric brain cancers such as diffuse midline glioma (DMG) and DIPG.

4 investors

Known Medicine develops a predictive engine using AI and patient datasets to identify optimal cancer treatments for individual patients. The company serves oncologists and cancer patients through computational analysis of biomaterials and drug-discovery data.

4 investors

Kolibri develops technology to manufacture cells using acoustic waves.

4 investors

Kronos Bio was a clinical-stage biopharmaceutical company developing small molecule therapeutics that target deregulated transcription factor networks implicated in cancer.

4 investors

Krosslinker develops aerogel-based materials for thermal insulation, including cooling paints, composite boards, and silica aerogel powders. Its products target industrial and building applications requiring lightweight, high-performance insulation.

4 investors

Quantum Lens develops a quantum computing and AI platform for drug discovery that simulates molecular behavior at the atomic level to guide the design of novel drug candidates. The platform targets pharmaceutical companies and biotech researchers working on small-molecule drug discovery, particularly for challenging targets like covalent inhibitors, hard-to-drug enzymes, and allosteric binding sites.

4 investors

Kuehnle AgroSystems (KAS) is a biotech company that uses a patented "dark fermentation" process and proprietary non-GMO microalgae strains to produce natural high-value products such as astaxanthin. It serves the food, feed, and health industries, targeting nutraceuticals, cosmetics, functional foods, and aquaculture and animal feed applications.

4 investors

Kupando is a biopharmaceutical company developing TLR 4/7 agonists that stimulate innate immunity for use in oncology and infectious diseases. Its lead candidate KUP101 combines a TLR4 and a TLR7 agonist in a liposomal formulation for treating solid tumors and preventing infectious diseases.

4 investors

Labforward develops digital software solutions for laboratory workflows and data management, serving research institutions, biotech companies, and regulated environments. The company integrates lab devices, data, and researchers through interconnected products for scientific discovery and compliance.

4 investors

A clinical-stage biopharmaceutical company developing small molecule therapies for schizophrenia, bipolar depression, and other neuropsychiatric disorders. Its lead candidate, LB-102, is an oral benzamide antipsychotic being developed for the U.S. market.

4 investors

Lenoss develops products aimed at advancing a physiological treatment pathway, supported by a team of industry professionals and clinical advisors. The company operates in the medical field with a focus on clinical treatment solutions.

4 investors

Leuko develops a noninvasive white blood cell monitor to track neutropenia risk in cancer patients and others undergoing treatment. The MIT spinout builds medical device hardware and AI imaging software for oncology and hematology care.

4 investors

Leyden Labs develops nasal sprays containing antibodies that target respiratory viruses such as influenza and COVID at the nasal mucosa to prevent initial infection and transmission. The company works on broadly protective antiviral products aimed at addressing endemic and pandemic respiratory threats.

4 investors

LimmaTech develops vaccine technologies and programs designed to combat antimicrobial-resistant pathogens and prevent severe infections. The company uses proprietary vaccine platform technology and engineered microorganisms to create vaccine solutions addressing emerging infectious diseases and antimicrobial resistance.

4 investors

Loop Genomics develops long-read DNA sequencing technology that converts short-read DNA sequencers into long-read sequencing machines, used across research and clinical applications.

4 investors

Building.life uses genetic engineering, genomic analysis, and AI to design novel organisms, beginning with engineering the world's first true unicorn through precision gene editing and embryonic development.

4 investors

LumiThera develops the Valeda Light Delivery System, an FDA-authorized photobiomodulation (PBM) device that applies multiple light wavelengths to treat early and intermediate dry age-related macular degeneration (AMD). The non-invasive treatment is intended for eyecare practitioners to help patients maintain or improve visual acuity.

4 investors

Mana.bio is a biotech company that uses machine learning and high-throughput screening to design lipid nanoparticles for targeted delivery of nucleic acid therapeutics and vaccines. The company aims to unlock RNA-based treatments for genetic diseases with unmet medical needs.

4 investors